Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
This study is currently recruiting participants.
Verified May 2013 by Ariad Pharmaceuticals
Sponsor:
Ariad Pharmaceuticals
Information provided by (Responsible Party):
Ariad Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01650805
First received: July 18, 2012
Last updated: May 7, 2013
Last verified: May 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is currently recruiting participants. |
|---|---|
| Estimated Study Completion Date: | June 2021 |
| Estimated Primary Completion Date: | June 2021 (Final data collection date for primary outcome measure) |